The investigational compound, MIM-D3, is currently in Phase 2 development. It has been developed by Mimetogen Pharmaceuticals and could potentially be a new class of agents called TrkA agonists.
Dry eye therapies on the market increase tear production without addressing tear quality. MIM-D3 stimulates mucin production, which removes allergens, pathogens and debris in addition to lubricating the eye.
More Articles on Ophthalmology:
University of Oklahoma’s Dean McGee Eye Institute Receives $110k Grant from Research to Prevent Blindness
Florida Society of Ophthalmology Presents Dr. William Mallon With Leadership Award
Dr. J. Ryan McManus Joins Munson Medical Center Staff
